<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic peripheral blood stem cell transplantation (Allo-PBSCT) has in recent years become an alternative to allogeneic bone marrow transplantation because it facilitates rapid hematopoietic reconstitution without an increase in the incidence of severe <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>We report on a 61-year-old man with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> who received an allo-PBSCT from his HLA-matched 68-year-old brother </plain></SENT>
<SENT sid="2" pm="."><plain>The preparative regimen consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were administered for GVHD prophylaxis </plain></SENT>
<SENT sid="4" pm="."><plain>The donor was treated with granulocyte colony-stimulating factor (G-CSF) at a dose of 10 micrograms/kg/day subcutaneously for 4 consecutive days </plain></SENT>
<SENT sid="5" pm="."><plain>A preparation of 4.04 x 10(6) CD34+ cells/kg recipient weight was collected in a single apheresis and infused immediately </plain></SENT>
<SENT sid="6" pm="."><plain>Engraftment times to a neutrophil count greater than 500/microliter and platelet count greater than 2.0 x 10(4)/microliter were 15 days each </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD of grade II developed, but was resolved with <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>However, the patient died of <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> 97 days after his allo-PBSCT </plain></SENT>
<SENT sid="9" pm="."><plain>Administration of G-CSF and apheresis in the donor were feasible and well tolerated </plain></SENT>
<SENT sid="10" pm="."><plain>Allo-PBSCT may result in earlier engraftment and be especially beneficial to elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>